Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    AGBA

    MCap

    USD77m

    Last close

    USD1.03

    ▲ 0.63 (157.50%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    Sareum Holdings

    MCap

    GBP28m

    Last close

    GBP0.27

    ▲ 6.25 (30.49%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Scandion Oncology (OMX: SCOL)

Last close As at 18/04/2024

1.36

▲ −0.03 (−2.16%)

Market capitalisation

SEK56m

Latest Insights

View More

Healthcare | Update

Scandion Oncology — An active quarter with AML plans in the mix

Flash note

Scandion Oncology — PANTAX Phase I trial meets primary endpoint

Healthcare | Flash note

Scandion Oncology — Expanding SCO-101 into AML

Healthcare | Update

Scandion Oncology — A defining year ahead for SCO-101
Visit Website

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (11.6) (39.0) (84.4)
Relative (9.5) (41.4) (86.2)
52 week high/low SEK8.7/SEK1.4

Financials

Edison Investment Research is terminating coverage on Scandion Oncology (SCOL). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec Revenue (DKKm) EBITDA (DKKm) PBT (DKKm) EPS (ore) P/E (x) P/CF (x)
2021A 0.8 (54.8) (57.2) (161.0) N/A N/A
2022A 2.1 (79.3) (82.2) (187.0) N/A N/A
2023E 0.6 (65.3) (65.3) (147.0) N/A N/A
2024E 0.6 (69.0) (69.4) (157.0) N/A N/A

Flash note

Healthcare

Scandion Oncology — PANTAX dosing schedule expanded

Flash note

Healthcare

Scandion Oncology — Outcome of rights issue

Initiation

Healthcare

Scandion Oncology — Chemotherapy overcoming drug resistance

edison tv

Healthcare

Scandion Oncology: Edison Open House Healthcare 2022

QuickView

Healthcare

Scandion Oncology — Drug-resistant cancer solutions